Futtsu

Researchers are evaluating the effectiveness of icotrokinra (JNJ-77242113) compared to a placebo in adults with active psoriatic arthritis (PsA). This study includes both participants who have previously used biologic treatments and those who have not. The goal is to assess how well the drug reduces the signs and symptoms of PsA by the 16th week of treatment. This is a Phase 3, multicenter, randomized, double-blind clinical trial designed to provide reliable evidence on the drug's impact on this condition. Participants will receive either icotrokinra or a placebo. The treatments will be administered according to the study protocol, but specific dosing details are not provided. Participants will be monitored over 16 weeks to evaluate their response to the treatment, focusing on the American College of Rheumatology (ACR) 20 response, which measures improvement in disease activity. The study compares the active drug against placebo to determine its efficacy and safety in this patient group. During the study, participants will undergo assessments to monitor their psoriatic arthritis symptoms, including joint swelling and tenderness, as well as blood tests to measure inflammation markers like C-reactive protein. Female participants who can become pregnant will have pregnancy tests before and during the study to ensure safety. Researchers will collect data on disease activity and safety throughout the study period to understand the treatment's effects. Total participation time and additional follow-up details are not specified.

Researchers are evaluating the effectiveness and safety of a study drug called JNJ-88545223 compared to a placebo in adults with active psoriatic arthritis (PsA). The goal is to see if treatment with JNJ-88545223 can reduce the signs and symptoms of PsA and improve the health of joints and skin. This is a phase 2b, randomized, double-blind, placebo-controlled study involving multiple centers. Participants will receive either JNJ-88545223 or a placebo orally. The study includes different dose levels to determine the best dose for treatment. The treatment period lasts for 16 weeks, during which the effects of the drug on PsA symptoms will be assessed. During the study, participants will be monitored to see how many achieve a 50% improvement in their symptoms according to the American College of Rheumatology criteria at week 16. Assessments may include joint evaluations, skin examinations, and laboratory tests such as C-reactive protein levels. Safety and response to treatment will be closely observed throughout the trial.